Felypressin: Mechanism, Dosing & Research Data

Felypressin is a synthetic vasopressin analog used exclusively in dental local anesthetic formulations as a vasoconstrictor. Unlike epinephrine (adrenaline), felypressin acts on V1 vasopressin receptors rather than adrenergic receptors, making it the preferred vasoconstrictor in patients who cannot tolerate epinephrine, including those on tricyclic antidepressants, non-selective MAO inhibitors, or with severe cardiovascular disease.

Mechanism of Action

V1AR/Gq/11 activation in vascular smooth muscle causes direct vasoconstriction independent of sympathetic nervous system
Local vasoconstriction at dental injection site: reduces local blood flow, slows local anesthetic absorption into systemic circulation, prolongs anesthetic duration
Reduces bleeding in surgical field by constricting mucosal blood vessels around injection site
No beta-adrenergic stimulation: unlike epinephrine, does not increase heart rate, cardiac output, or systolic blood pressure significantly at dental doses
Minimal antidiuretic activity at dental doses (much weaker than vasopressin at V2 receptor; designed for V1 selectivity)

Research Findings

Felypressin 0.03 IU/mL in 3% prilocaine: equivalent duration of dental anesthesia to 2% lidocaine with 1:100,000 epinephrine in controlled trials
Cardiovascular safety: felypressin produces significantly smaller increases in mean arterial pressure and heart rate vs epinephrine in patients with hypertension
TCA interaction avoidance: felypressin used safely in patients on amitriptyline/imipramine where epinephrine causes potentially dangerous hypertensive episodes due to norepinephrine reuptake inhibition
Pulpal anesthesia depth: felypressin-containing formulas provide adequate pulpal anesthesia for routine dental procedures; slightly less depth than epinephrine-containing for complex procedures
In vitro: felypressin at 0.03 IU/mL produced 60-70% reduction in gingival blood flow measured by laser Doppler in dental volunteers

Research Protocols

Standard dental formulation: 3% prilocaine with 0.03 IU/mL felypressin (Citanest with Octapressin); 1.7-2.2 mL cartridge per injection site
Maximum dose: generally 4-6 cartridges per appointment; felypressin contributes ~0.2-0.3 IU total vasopressin per visit (well below systemic vasopressor doses)
Cardiovascular patients: preferred over epinephrine-containing formulas in patients with uncontrolled hypertension or TCA use
Not recommended in pregnancy (V1 uterine receptors; risk of uterine contractions) or severe cardiovascular disease

Interactions

Tricyclic antidepressants (amitriptyline, imipramine): epinephrine with TCAs causes extreme blood pressure rise; felypressin is safer alternative
MAO inhibitors (phenelzine, tranylcypromine): epinephrine risk increased; felypressin safer but consult physician before use
Oxytocin: V1/oxytocin receptor overlap; high felypressin doses theoretically could compete; not clinically relevant at dental doses

Safety Profile

Excellent safety in dental applications over decades of use. Contraindicated in pregnancy (uterotonic risk via V1R on uterus). Use with caution in ischemic heart disease (coronary V1R constriction possible at high doses). Not for IV use. Local tissue ischemia possible if injected into confined spaces.